Table 3.
Differential risk stratification of patients with discordant scores based on Clinical Oncotype Dx and NanoString Oncotype Dx recurrence scores
| Number of Patients | Risk from Clinical Oncotype Dx recurrence scores (clinRS) | Risk from NanoString Oncotype Dx recurrence scores (nstringRS) |
|---|---|---|
| 7/71 (9.9%) | Low | Intermediate |
| 4/71 (5.6%) | Intermediate | High |
| 5/71 (7.0%) | Intermediate | Low |
| 1/71 (1.4%) | High | Intermediate |